JNJ · News · 20260906N

Neuroscience Pipeline Progress

JOHNSON & JOHNSON · 2026-09-06 · Importance 23 · Surprise 24

Johnson & Johnson will present 24 abstracts at the 2026 Psych Congress Annual Meeting in New Orleans from September 15–19. The portfolio updates include pivotal Phase 3 CAPLYTA data in adults with bipolar mania, new SPRAVATO analyses focused on anhedonia, and Phase 3 seltorexant data as an adjunctive treatment for major depressive disorder with insomnia. Additional real-world evidence covers schizophrenia-related hospitalizations and treatment satisfaction for the company’s paliperidone palmitate injectable portfolio.

Key facts